There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 8 | 81 | 1652.9 |
| 2 | 5 | 1652.8 |
| 2 | 18 | 1652.5 |
| 1 | 6 | 1652.4 |
| 2 | 14 | 1652.3 |
| Ask | Qty | Orders |
|---|---|---|
| 1653.5 | 3 | 28 |
| 1653.7 | 2 | 7 |
| 1653.8 | 1 | 1 |
| 1653.9 | 1 | 1 |
| 1654 | 1 | 4 |
Annual Revenue,rose 12.35%, in the last year to ₹3,956.31 Cr. Its sector's average revenue growth for the last fiscal year was 10.62%.Annual Net Profit,rose 19.35% in the last year to ₹659.58 Cr. Its sector's average net profit growth for the last fiscal year was 36.73%.Price to Earning Ratio,is 37.91, lower than its sector PE ratio of 40.67.
J.B. Chemicals & Pharmaceuticals Ltd. (JB Pharma) is an Indian pharmaceutical company incorporated on December 18, 1976, with a 49-year legacy of developing and marketing medicines across multiple therapies and dosage forms. The company manufactures and markets pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs), supported by eight state-of-the-art multi‑dosage formulation plants in India with key global regulatory approvals. Product capabilities span oral solids, injectables, liquids and lozenges; JB Pharma is among the few Indian companies to implement OROS (osmotic-controlled release oral drug delivery system) technology and ranks among the top five global manufacturers of medicated and herbal lozenges.
The company serves patients across 40+ regulated and semi‑regulated markets through direct operations and distributors, with a direct front‑end presence via four international subsidiaries; exports include generics to the USA, UK, South Africa, Australia and Canada, and branded generics to parts of Africa, South‑East Asia, the Gulf, the Middle East, and Central and South America. In India, JB Pharma ranks among the top 10 in cardiology with three brands in the therapy’s top 25, and six of its brands feature in the top 300 of the Indian Pharmaceutical Market (IPM) as of March 2025. The company operates 47 domestic locations (including corporate and regional offices, C&F sites, warehouses and an R&D centre) and maintains four international offices in Russia, South Africa, Dubai and the Philippines.
J.B. Chemicals & Pharmaceuticals Ltd Key milestones achieved in FY25
JB Pharma manufactures and markets pharmaceutical formulations, herbal products and APIs, with strengths in oral solids, injectables, liquids and lozenges. It also deploys advanced delivery technologies such as OROS and is among the top five producers of medicated and herbal lozenges globally.
The company serves 40+ markets through direct operations and distributors, and maintains four international subsidiaries for front‑end presence. Exports contributed 38 Per cent of turnover in FY 2024–25, and the USA generics business is serviced through an asset‑light distributor model with over 17 ANDAs approved.
JB Pharma operates eight multi‑dosage formulation plants in India and 47 domestic locations, including offices, warehouses and an R&D centre. Six brands rank among the top 300 in the IPM, and the company is among the top 10 in cardiology in India.
